Suppr超能文献

基质金属蛋白酶9表达在骨肉瘤中的预后意义:16项研究的荟萃分析

Prognostic significance of matrix metalloproteinase 9 expression in osteosarcoma: A meta-analysis of 16 studies.

作者信息

Zhou Jian, Liu Tang, Wang Wanchun

机构信息

Department of Orthopedics, The Second Xiangya Hospital.

Department of Sports Medicine Research Center, Central South University, Changsha, Hunan, China.

出版信息

Medicine (Baltimore). 2018 Nov;97(44):e13051. doi: 10.1097/MD.0000000000013051.

Abstract

BACKGROUND

Matrix metalloproteinase 9 (MMP-9) is significant in the progression of osteosarcoma (OS) via increasing tumor growth, invasion and metastasis. Although previous reports indicate the prognostic value of MMP-9 in OS, there is still a great degree on inconsistency between studies. Here we report a comprehensive evaluation of the value of MMP-9 in metastasis of OS by conducting a meta-analysis of published studies.

METHODS

The quantity of the studies was evaluated using the Newcastle-Ottawa quality assessment scale (NOS). Sixteen studies with a total of 816 patients with OS were examined and we calculated the pooled odds ratio (OR) with corresponding 95% confidence interval (CI) (95% CI) to evaluate that the positive expression of MMP-9 predicts neoplasm metastasis and poor survival in OS.

RESULTS

The results of Meta-analysis indicated that patients with positive expression of MMP-9 were significantly associated with neoplasm metastasis (OR = 4.69, 95% CI: 3.05-7.21, P <.001) and poor survival in OS with the pooled OR of 7.19 (95% CI 4.32-11.98, P <.001) when compared to their counterparts with a negative expression of MMP-9. The results of sensitivity analysis showed that the pooled OR was stable. It doesn't significantly change when a single study was removed.

CONCLUSIONS

The results of meta-analysis indicated that MMP-9 may be a prognostic biomarker guiding the clinical therapy for OS.

摘要

背景

基质金属蛋白酶9(MMP - 9)通过促进肿瘤生长、侵袭和转移,在骨肉瘤(OS)进展中具有重要意义。尽管先前的报道指出了MMP - 9在骨肉瘤中的预后价值,但研究之间仍存在很大程度的不一致。在此,我们通过对已发表研究进行荟萃分析,全面评估MMP - 9在骨肉瘤转移中的价值。

方法

使用纽卡斯尔 - 渥太华质量评估量表(NOS)评估研究质量。对16项研究共816例骨肉瘤患者进行了检查,我们计算了合并比值比(OR)及相应的95%置信区间(CI),以评估MMP - 9的阳性表达是否预示骨肉瘤的肿瘤转移和不良生存情况。

结果

荟萃分析结果表明,与MMP - 9阴性表达的患者相比,MMP - 9阳性表达的患者与肿瘤转移显著相关(OR = 4.69,95% CI:3.05 - 7.21,P <.001),且骨肉瘤患者生存不良,合并OR为7.19(95% CI 4.32 - 11.98,P <.001)。敏感性分析结果显示合并OR值稳定。剔除单个研究时,该值无显著变化。

结论

荟萃分析结果表明,MMP - 9可能是指导骨肉瘤临床治疗的预后生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3cbb/6221749/bb5f404d1729/medi-97-e13051-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验